UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Glucagon-like peptide 1 (GLP-1)

Molecular metabolism (Germany), 2019-12, Vol.30, p.72-130

2019

Link zum Volltext

Verfügbarkeit prüfen

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Diabetes, obesity & metabolism, 2009-12, Vol.11 (12), p.1163-1172

2009

Link zum Volltext

Verfügbarkeit prüfen

Spontanhypoglykämien

Diabetologie (Online), 2013-02, Vol.9 (1), p.47-54

2013

Link zum Volltext

Verfügbarkeit prüfen

No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects

Peptides (New York, N.Y. : 1980), 2020-03, Vol.125, p.170176-170176, Article 170176

2020

Link zum Volltext

Verfügbarkeit prüfen

Inkretinmimetika und Inkretinverstärker

Diabetologie (Online), 2007-09, Vol.3 (5), p.387-398

Nauck, M.A

2007

Link zum Volltext

Verfügbarkeit prüfen

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients

Diabetic medicine, 1998-11, Vol.15 (11), p.937-945

1998

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

American journal of physiology: endocrinology and metabolism, 1997-11, Vol.273 (5), p.E981-E988

1997

Link zum Volltext

Verfügbarkeit prüfen

Durabilité de l’efficacité du contrôle glycémique sous liraglutide dans l’étude LEADER

Annales d'endocrinologie, 2018-09, Vol.79 (4), p.273-273

2018

Link zum Volltext

Verfügbarkeit prüfen

Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?

Diabetes, obesity & metabolism, 2009-03, Vol.11 (3), p.213-222

2009

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycemic Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin

Canadian journal of diabetes, 2008, Vol.32 (4), p.329-329

2008

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycem1c Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin

Canadian journal of diabetes, 2008, Vol.32 (4), p.329-329

2008

Link zum Volltext

Verfügbarkeit prüfen

Description des infarctus du myocarde et des sous-types dans l’étude LEADER

Annales d'endocrinologie, 2017-09, Vol.78 (4), p.400-401

2017

Link zum Volltext

Verfügbarkeit prüfen

Pas d’interaction entre le bénéfice cardiovasculaire procuré par le liraglutide dans l’étude LEADER et l’existence d’une insuffisance cardiaque

Annales d'endocrinologie, 2018-09, Vol.79 (4), p.267-267

2018

Link zum Volltext

Verfügbarkeit prüfen

Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes

Diabetes, obesity & metabolism, 2008, Vol.10 (1), p.18-33

2008

Link zum Volltext

Verfügbarkeit prüfen

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure

Diabetes care, 1998-11, Vol.21 (11), p.1925

1998

Link zum Volltext

Verfügbarkeit prüfen

Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)

European heart journal, 2000-02, Vol.21 (3), p.220-229

2000

Link zum Volltext

Verfügbarkeit prüfen

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to α-glucosidase inhibition (acarbose) in Type 2 diabetic patients

Diabetic medicine, 1998-06, Vol.15 (6), p.485-491

1998

Link zum Volltext

Verfügbarkeit prüfen

Évaluation des effets cardiovasculaires du liraglutide : Conception et données de base de l’étude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

Médecine des maladies métaboliques, 2015-05, Vol.9 (3), p.316-328

2015

Link zum Volltext

Verfügbarkeit prüfen

Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia

Human mutation, 2001-08, Vol.18 (2), p.165-166

2001

Link zum Volltext

Verfügbarkeit prüfen

Spontanhypoglykämien: Insulinome und Differenzialdiagnosen

Diabetologe, 2013-02, Vol.9 (1), p.47-54

2013

Link zum Volltext

Verfügbarkeit prüfen

Inkretinmimetika und Inkretinverstärker: Neue Diabetesmedikamente auf der Basis physiologischer insulinsekretionssteigernder Darmhormone

Diabetologe, 2007-09, Vol.3 (5), p.387-398

Nauck, M.A.

2007

Link zum Volltext

Verfügbarkeit prüfen

Rapid genotyping of human platelet antigen 1 (HPA-1) with fluorophore-labeled hybridization probes on the lightcycler

Atherosclerosis, 1999-05, Vol.144, p.63-63

1999

Link zum Volltext

Verfügbarkeit prüfen

Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia: Mutations in Brief

Human mutation, 2001-08, Vol.18 (2), p.165-166

2001

Link zum Volltext

Verfügbarkeit prüfen

Influence of glycyemic control on size of myocardial infarction and long-term survival of type 2 diabetic patients

Diabetes research and clinical practice, 2000-09, Vol.50, p.300-301

2000

Link zum Volltext

Verfügbarkeit prüfen

Absence of severe hyperinsulinemia after pancreas/kidney transplantation with peripheral venous drainage

Transplantation proceedings, 1997-02, Vol.29 (1), p.645-646

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(14)
Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Endocrinology & Metabolism
(10)
Female
(10)
Male
(10)
Blood Glucose - Metabolism
(9)
Diabetes Mellitus, Type 2 - Drug Therapy
(7)
Glucagon
(7)
Hypoglycemic Agents - Therapeutic Use
(7)
Insulin Secretion
(7)
Middle Aged
(7)
Aged
(6)
Biological And Medical Sciences
(6)
Diabetes
(6)
Glucagon-Like Peptide 1
(6)
Insulin - Blood
(6)
Medical Sciences
(6)
Adult
(5)
Insulin - Metabolism
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Glucagon-like peptide 1 (GLP-1)

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Spontanhypoglykämien

No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects

Inkretinmimetika und Inkretinverstärker

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2 diabetic patients

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Durabilité de l’efficacité du contrôle glycémique sous liraglutide dans l’étude LEADER

Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?

Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycemic Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin

Liraglutide, a Once-daily Human GLP-1 Analog, In Type 2 Diabetes Provides Similar Glycem1c Control with Reduced Body Weight Compared with Glimepiride when Added to Metformin

Description des infarctus du myocarde et des sous-types dans l’étude LEADER

Pas d’interaction entre le bénéfice cardiovasculaire procuré par le liraglutide dans l’étude LEADER et l’existence d’une insuffisance cardiaque

Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure

Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to α-glucosidase inhibition (acarbose) in Type 2 diabetic patients

Évaluation des effets cardiovasculaires du liraglutide : Conception et données de base de l’étude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia

Spontanhypoglykämien: Insulinome und Differenzialdiagnosen

Inkretinmimetika und Inkretinverstärker: Neue Diabetesmedikamente auf der Basis physiologischer insulinsekretionssteigernder Darmhormone

Rapid genotyping of human platelet antigen 1 (HPA-1) with fluorophore-labeled hybridization probes on the lightcycler

Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia: Mutations in Brief

Influence of glycyemic control on size of myocardial infarction and long-term survival of type 2 diabetic patients

Absence of severe hyperinsulinemia after pancreas/kidney transplantation with peripheral venous drainage

Suchergebnisse filtern